MESO

Mesoblast Ltd Sponsored ADR (MESO) | Rumor.io

Mesoblast

MESO

Attention (50-day avg)0%

Attention rank (50-day avg)#1,803

Bullish sentiment (50-day avg)100%

Price to earnings ratio0.12

Market capitalization1.9B

Earnings per share-0.44

Dividend yield (TTM)—

Revenue (annual)120.3M

Net income (annual)-57.5M

Social

What share of all stock conversation is about MESO?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% 0	0% +0	0% 0

Aug 27

Mesoblast Limited (MESO) reported FY2026 earnings, with total revenue increasing 599% to $120.25m and a 91.2% gross profit margin.
The company's reported loss narrowed 44% to $57.5m, with $103.1m of new Ryoncil revenue contributing to a $11.9m improvement in loss.
Mesoblast's Q4 revenue rose 34.2% and the company has a $10B TAM in chronic low back pain (CLBP) alone, with additional opportunities in SR-aGvHD, heart failure, and DMD.

Generated by AI

Sentiment

Of the messages about MESO that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	100% 0	100% 0	91.27% +0.84
Bearish	—	0% 0	0% 0	8.73% -0.84

Bullish· Jul 18

$MESO has achieved significant revenue growth from Ryoncil sales, reaching $13.2 million in the first quarter post-launch.
Strong insider buying activity, with insiders loading up $200 million worth of stock, suggests confidence in the company's future prospects.
The commercial launch of Ryoncil and the company's additional pipeline of products position $MESO for potential long-term growth and a "multibagger" return.

Bearish· Mar 26

$MESO's price broke down quickly from a flag formation, indicating decreasing buying pressure and potentially continuing downtrend.
The stock has been showing signs of exhaustion and rejection at key levels, with some traders experiencing losses or regret from buying at the top.
$MESO's price may be due for a dip, with some traders waiting for a pullback below $3 or hoping for a quick decline to re-enter the market.

Generated by AI

Topics

Of the messages about MESO that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	100%	100%	30.82%
Controversies	—	0%	0%	2.84%
Earnings	—	0%	0%	7.34%
Analysts	—	0%	0%	21.53%
Macro	—	0%	0%	27.2%
Technical Analysis	—	0%	0%	10.27%

Announcements· Jul 18

Mesoblast's Ryoncil has achieved $13.2 million in gross revenue from sales in its first quarter post-launch, a significant increase from $6 million in 2024.
The company has reported strong initial results from the commercial launch of Ryoncil, with 7-year orphan drug exclusivity and biologic exclusivity through 2036, and robust cash reserves.
Ryoncil is the first FDA-approved mesenchymal stromal cell (MSC) product in the US, and has generated $1.6 million in royalties from TEMCELL sales in Japan, with broad US coverage now in place.

Technical Analysis· Apr 1

The EMA crossover indicator on $MESO has been triggered at $6.11 and $6.04, indicating a potential long-term trend reversal.
$MESO has shown a strong trend of bouncing back from support levels, with the stock experiencing a 1.10 increase to 7.36 after a brief dip.
The stock has been identified as a potential long-term gem, with a strong possibility of breaking through the $6.80 resistance level and reaching $7.00-$7.90.

Generated by AI

Community

Of the messages about MESO, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	11.25%	11.85%	48.6%
Newcomers	—	88.75%	88.15%	51.4%

Regulars· Jul 18

Mesoblast Limited has achieved $13.2 million in gross revenue from Ryoncil sales in its first quarter post-launch, a significant increase from $6 million in 2024.
The successful commercial launch of Ryoncil has led to a strong market position for Mesoblast, with 7-year orphan drug exclusivity and biologic exclusivity through 2036.
Mesoblast's unaudited Q2 revenue from Ryoncil sales reached $13.2 million, with Ryoncil being the first FDA-approved MSC therapy for pediatric SR-aGvHD.

Newcomers· Jul 18

The commercial launch of Mesoblast's Ryoncil therapy has been successful, with $13.2 million in gross sales in the second quarter and $1.6 million in royalties from TEMCELL sales in Japan.
The stock is experiencing a significant surge in price, with a 22% increase in pre-market trading, and volume expansion confirms a breakout pattern.
The momentum behind Mesoblast's stock is uncertain, with some speculating that it may be due to a biotech catalyst or institutional entry, but the strong volume and price action suggest a bullish trend.

Generated by AI

News

Mesoblast Files 2026 Form 20-F, Affirms Status as Well-Known Issuer

Tipranks Press Release.

1mo agoThe Globe and Mail

Mesoblast Fiscal 2026 Loss Narrows, Revenue Rises

1mo agoYahoo Finance

Mesoblast Reports Substantial Revenue Growth to US$120M

RYONCIL Market Share Expands; Phase 3 Back Pain Trial Completes Treatment

1mo agoBarchart.com

Also Discussed

Investors talking about MESO also mention

#	Name	Attention
1	Mesabi TrustMSB	0%new
2	ATHX - Athersys, Inc.	——
3	BioRestorative Therapies, Inc.BRTX	0%0
4	Capricor Therapeutics, Inc.CAPR	0.35%+0.26
5	Vericel CorporationVCEL	0%0
6	MicroCloud Hologram Inc.HOLO	0%0
7	BCLI - Brainstorm Cell Therapeutics Inc.	——
8	Mainz Biomed N.V.MYNZ	0%new
9	Alset Inc.AEI	0%0
10	ATXS - Astria Therapeutics, Inc.	——

Mesoblast Ltd Sponsored ADR

Healthcare
Biotechnology

Mesoblast Ltd Sponsored ADR is a biotechnology company focused on developing regenerative medicine products and allogeneic, off-the-shelf cellular therapies. The company’s platform is built around mesenchymal lineage cell technology designed for use across severe inflammatory and immune-mediated conditions, as well as selected cardiovascular and spine-related disorders. Its current pipeline includes cell-based medicines intended for hospital and specialist care settings, reflecting a focus on complex diseases with limited treatment options. Mesoblast operates through research, development, and commercialization activities across multiple regions, including Australia, the United States, Singapore, and Switzerland. As an ADR, Mesoblast Ltd Sponsored ADR gives U.S. investors access to the company’s underlying ordinary shares while representing a global healthcare business centered on advanced cell therapy and regenerative medicine.

Website

Location

55 Collins Street

Melbourne, VIC, 3000

Australia

Social

What share of all stock conversation is about MESO?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% 0	0% +0	0% 0

Aug 27

Mesoblast Limited (MESO) reported FY2026 earnings, with total revenue increasing 599% to $120.25m and a 91.2% gross profit margin.
The company's reported loss narrowed 44% to $57.5m, with $103.1m of new Ryoncil revenue contributing to a $11.9m improvement in loss.
Mesoblast's Q4 revenue rose 34.2% and the company has a $10B TAM in chronic low back pain (CLBP) alone, with additional opportunities in SR-aGvHD, heart failure, and DMD.

Generated by AI

Sentiment

Of the messages about MESO that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	100% 0	100% 0	91.27% +0.84
Bearish	—	0% 0	0% 0	8.73% -0.84

Bullish· Jul 18

$MESO has achieved significant revenue growth from Ryoncil sales, reaching $13.2 million in the first quarter post-launch.
Strong insider buying activity, with insiders loading up $200 million worth of stock, suggests confidence in the company's future prospects.
The commercial launch of Ryoncil and the company's additional pipeline of products position $MESO for potential long-term growth and a "multibagger" return.

Bearish· Mar 26

$MESO's price broke down quickly from a flag formation, indicating decreasing buying pressure and potentially continuing downtrend.
The stock has been showing signs of exhaustion and rejection at key levels, with some traders experiencing losses or regret from buying at the top.
$MESO's price may be due for a dip, with some traders waiting for a pullback below $3 or hoping for a quick decline to re-enter the market.

Generated by AI

Topics

Of the messages about MESO that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	100%	100%	30.82%
Controversies	—	0%	0%	2.84%
Earnings	—	0%	0%	7.34%
Analysts	—	0%	0%	21.53%
Macro	—	0%	0%	27.2%
Technical Analysis	—	0%	0%	10.27%

Announcements· Jul 18

Mesoblast's Ryoncil has achieved $13.2 million in gross revenue from sales in its first quarter post-launch, a significant increase from $6 million in 2024.
The company has reported strong initial results from the commercial launch of Ryoncil, with 7-year orphan drug exclusivity and biologic exclusivity through 2036, and robust cash reserves.
Ryoncil is the first FDA-approved mesenchymal stromal cell (MSC) product in the US, and has generated $1.6 million in royalties from TEMCELL sales in Japan, with broad US coverage now in place.

Technical Analysis· Apr 1

The EMA crossover indicator on $MESO has been triggered at $6.11 and $6.04, indicating a potential long-term trend reversal.
$MESO has shown a strong trend of bouncing back from support levels, with the stock experiencing a 1.10 increase to 7.36 after a brief dip.
The stock has been identified as a potential long-term gem, with a strong possibility of breaking through the $6.80 resistance level and reaching $7.00-$7.90.

Generated by AI

Community

Of the messages about MESO, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	11.25%	11.85%	48.6%
Newcomers	—	88.75%	88.15%	51.4%

Regulars· Jul 18

Mesoblast Limited has achieved $13.2 million in gross revenue from Ryoncil sales in its first quarter post-launch, a significant increase from $6 million in 2024.
The successful commercial launch of Ryoncil has led to a strong market position for Mesoblast, with 7-year orphan drug exclusivity and biologic exclusivity through 2036.
Mesoblast's unaudited Q2 revenue from Ryoncil sales reached $13.2 million, with Ryoncil being the first FDA-approved MSC therapy for pediatric SR-aGvHD.

Newcomers· Jul 18

The commercial launch of Mesoblast's Ryoncil therapy has been successful, with $13.2 million in gross sales in the second quarter and $1.6 million in royalties from TEMCELL sales in Japan.
The stock is experiencing a significant surge in price, with a 22% increase in pre-market trading, and volume expansion confirms a breakout pattern.
The momentum behind Mesoblast's stock is uncertain, with some speculating that it may be due to a biotech catalyst or institutional entry, but the strong volume and price action suggest a bullish trend.

Generated by AI

Mesoblast

Social

Aug 27

Bullish· Jul 18

Bearish· Mar 26

Announcements· Jul 18

Technical Analysis· Apr 1

Regulars· Jul 18

Newcomers· Jul 18

Mesoblast wins FDA nod for new potency assay for Ryoncil

Cantor Fitzgerald reiterates Mesoblast stock rating on adult trial focus

Mesoblast receives FDA approval for new potency assay for Ryoncil

Mesoblast Files 2026 Form 20-F, Affirms Status as Well-Known Issuer

Mesoblast Fiscal 2026 Loss Narrows, Revenue Rises

Mesoblast Reports Substantial Revenue Growth to US$120M

Also Discussed

Mesoblast Ltd Sponsored ADR

Company Information

Location

Mesoblast wins FDA nod for new potency assay for Ryoncil

Cantor Fitzgerald reiterates Mesoblast stock rating on adult trial focus

Mesoblast receives FDA approval for new potency assay for Ryoncil

Mesoblast Files 2026 Form 20-F, Affirms Status as Well-Known Issuer

Mesoblast Fiscal 2026 Loss Narrows, Revenue Rises

Mesoblast Reports Substantial Revenue Growth to US$120M

Also Discussed

Social

Aug 27

Bullish· Jul 18

Bearish· Mar 26

Announcements· Jul 18

Technical Analysis· Apr 1

Regulars· Jul 18

Newcomers· Jul 18